EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pulmonary arterial hypertension: Risk stratification and selection of combination therapy

Rafael Berger Simionato, Olívia Lazotti Vieira, Heloísa Noronha Facioli, Gabriela Leitão Cabral, Maria Luísa de Paula Rodrigues

International Health Sciences Review · 30.10.2026 · 2 (5)

DOI: 10.70164/ihsr.v2i5.254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Health Sciences Review, online erschienen am 30.10.2026. Verfasst von Rafael Berger Simionato und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary arterial hypertension requires repeated assessment of right ventricular vulnerability and timely use of therapies with complementary mechanisms. This narrative critical review examines diagnostic boundaries, contemporary risk models, initial combination treatment, escalation strategies, and the changing role of sotatercept using primary trials, registry studies, and guidance available through October 2026. A comprehensive assessment remains essential at diagnosis, whereas four-stratum models improve discrimination within the large intermediate-risk population during follow-up. Functional class, walking distance, and natriuretic peptides provide a practical core but cannot replace imaging, hemodynamics, and clinical judgment. Initial endothelin receptor antagonist and phosphodiesterase-5 inhibitor therapy is supported for many patients with established pulmonary arterial hypertension; high-risk presentations require consideration of combinations including parenteral prostacyclin. Oral triple therapy has not demonstrated the same evidence as parenteral regimens. Sotatercept improves exercise capacity and reduces clinical events as add-on treatment, with recent trials extending evidence to advanced and recently diagnosed disease. The September 2026 European Respiratory Society update recommends add-on sotatercept for patients remaining above low risk, while acknowledging uncertainty in low-risk populations. Treatment selection must consider phenotype, tolerability, delivery burden, and monitoring requirements. Persistent intermediate-high or high risk should prompt timely therapeutic intensification and transplant evaluation rather than reliance on a favorable isolated measurement.

Zitieren

APA

Simionato, R. B., Vieira, O. L., Facioli, H. N., Cabral, G. L., & Rodrigues, M. L. D. P. (2026). Pulmonary arterial hypertension: Risk stratification and selection of combination therapy. International Health Sciences Review, 2(5). https://doi.org/10.70164/ihsr.v2i5.254

Vancouver

Simionato RB, Vieira OL, Facioli HN, Cabral GL, Rodrigues MLDP. Pulmonary arterial hypertension: Risk stratification and selection of combination therapy. International Health Sciences Review. 2026;2(5). doi:10.70164/ihsr.v2i5.254

BibTeX
@article{Simionato2026,
  author = {Simionato, Rafael Berger and Vieira, Olívia Lazotti and Facioli, Heloísa Noronha and Cabral, Gabriela Leitão and Rodrigues, Maria Luísa de Paula},
  title = {Pulmonary arterial hypertension: Risk stratification and selection of combination therapy},
  journal = {International Health Sciences Review},
  year = {2026},
  volume = {2},
  number = {5},
  doi = {10.70164/ihsr.v2i5.254}
}
Kostenlos starten →